Healthy Clinical Trial
Official title:
A Double Blind, Randomized, Single Center, Single and Multiple Dose, Pharmacokinetic, Safety and Tolerability Study of Recombinant Human Alkaline Phosphatase (recAP) Administered Intravenously in Healthy Japanese Subjects
Verified date | March 2022 |
Source | AM-Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Clinical Phase 1 study to investigate the pharmacokinetics and to assess the safety and tolerability of recAP after single and multiple intravenous doses in healthy Japanese subjects.
Status | Completed |
Enrollment | 34 |
Est. completion date | December 31, 2021 |
Est. primary completion date | July 8, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Gender : male 2. Age : 20-55 years, inclusive 3. Body mass index (BMI) : 18.0-30.0 kg/m2, inclusive 4. Subjects must be Japanese by birth, have resided outside Japan <10 years, have parents and maternal and paternal grandparents who are Japanese, and primarily consume a Japanese diet. 5. Resting supine blood pressure at screening showing no clinically relevant deviations from normal as judged by the Principal Investigator. 6. Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations. 7. All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator. 8. Ability and willingness to abstain from alcohol and tobacco products from 48 h prior to entry in the clinical research center until discharge. 9. Easily accessible veins for venipuncture and catheter placing. 10. Willingness to sign the written informed consent form (ICF). 11. Subjects must agree to use adequate contraception when sexually active. This applies for the time period between end of first administration and 14 days after the last administration of study drug. Exclusion Criteria: 1. Evidence of clinically relevant pathology. 2. History of relevant drug and/or food allergies. 3. Subject has a history of clinically significant abnormalities or of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study. 4. Use of medication, except for acetaminophen (paracetamol), which is allowed up to 3 days before entry into the clinical research center (after that time the use of a limited amount of acetaminophen is permitted after consultation with the Principal Investigator). 5. Subject is mentally or legally incapacitated, has significant emotional problems at the time of screening visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder over the last year. 6. Participation in a drug study within 60 days prior to drug administration. 7. Donation of more than 500 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 liters of blood (for men) in the 10 months preceding the start of this study 8. Smoking more than 5 cigarettes, 1 cigar or 1 pipe daily. 9. History of alcohol abuse or drug addiction (including soft drugs like cannabis products). 10. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants) and/or alcohol breath test at Screening and/or Pre-Dose. 11. Intake of more than 14 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine/Japanese Sake or 35 mL of spirits). 12. Positive screen on hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) or anti-human immunodeficiency virus (anti-HIV)-1 or anti-HIV-2 or HIV-1/2 antigen. 13. Illness within 5 days prior to (the first) drug administration. |
Country | Name | City | State |
---|---|---|---|
Japan | P-One Clinic, Keikokai Medical Corporation | Tokyo |
Lead Sponsor | Collaborator |
---|---|
AM-Pharma |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum observed recAP plasma concentration (Cmax) after single dose | Blood collection for cmax evaluation daily from Day 1 to Day 9 | Single dose 9 days treatment phase | |
Primary | Time to attain maximum recAP serum concentration (Tmax) after single dose | Blood collection for Tmax evaluation daily from Day 1 to Day 9 | Single dose 9 days treatment phase | |
Primary | Area under the plasma concentration versus time curve (AUC) after single dose | Blood collection for AUC evaluation daily from Day 1 to Day 9 | Single dose 9 days treatment phase | |
Primary | recAP elimination half-life ( t1/2) after single dose | Blood collection for t1/2 evaluation daily from Day 1 to Day 9 | Single dose 9 days treatment phase | |
Primary | Maximum observed recAP plasma concentration (Cmax) after multiple doses | Blood collection for cmax evaluation daily from Day 1 to Day 13 | Multiple doses 13 days treatment phase | |
Primary | Time to attain maximum recAP serum concentration (Tmax) after multiple doses | Blood collection for Tmax evaluation daily from Day 1 to Day 13 | Multiple doses 13 days treatment phase | |
Primary | Area under the plasma concentration versus time curve (AUC) after multiple doses | Blood collection for AUC evaluation daily from Day 1 to Day 13 | Multiple doses 13 days treatment phase | |
Primary | recAP elimination half-life ( t1/2) after multiple doses | Blood collection for t1/2 evaluation daily from Day 1 to Day 13 | Multiple doses 13 days treatment phase | |
Secondary | Adverse events (AEs) after single dose | Any untoward medical occurrence in a subject enrolled into a clinical study regardless of its causal relationship to study drug. | Single dose 9 days treatment phase | |
Secondary | Adverse events (AEs) after multiple doses | Any untoward medical occurrence in a subject enrolled into a clinical study regardless of its causal relationship to study drug. | Multiple doses 13 days treatment phase |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |